Amygdala responses to quetiapine XR and citalopram treatment in major depression : the role of 5-HTTLPR-S/Lg polymorphisms
Copyright © 2016 John Wiley & Sons, Ltd..
OBJECTIVES: Genotype and drug pharmacology may contribute to variations in brain response to antidepressants. We examined the impact of two antidepressants with differential actions on serotonin transporter and the 5-HHTLPR-S/Lg polymorphisms on amygdala responses in major depressive disorder (MDD).
METHODS: Caucasians with MDD were given either citalopram or quetiapine extended release for 8 weeks. Patients were genotyped for 5-HTTLPR. Clinical efficacy was assessed using the Hamilton Depression Rating Scale. fMRI responses to negative emotional faces were acquired at baseline, week 1 and week 8. The outcome measure was change in amygdala responses at week 8.
RESULTS: Citalopram had no effect on amygdala responses in MDD patients with S/Lg alleles at weeks 1 and 8 compared with baseline, whereas it induced changes in amygdala responses in LL homozygotes. By contrast, quetiapine decreased amygdala responses at both time points in S/Lg carriers, and changes in amygdala responses at week 8 correlated with a reduction in depression scores. The small number of LL homozygotes in quetiapine group was a limitation. Efficacy of both treatments was comparable.
CONCLUSIONS: These preliminary data suggest that pharmacological mechanisms and genetics need to be considered in the development of neuroimaging markers for the evaluation of antidepressant treatments.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Human psychopharmacology - 31(2016), 2 vom: 01. März, Seite 144-55 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ramasubbu, Rajamannar [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.12.2016 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/hup.2521 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM257495266 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM257495266 | ||
| 003 | DE-627 | ||
| 005 | 20231224182944.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/hup.2521 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0858.xml |
| 035 | |a (DE-627)NLM257495266 | ||
| 035 | |a (NLM)26879101 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ramasubbu, Rajamannar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Amygdala responses to quetiapine XR and citalopram treatment in major depression |b the role of 5-HTTLPR-S/Lg polymorphisms |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.12.2016 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2016 John Wiley & Sons, Ltd. | ||
| 520 | |a OBJECTIVES: Genotype and drug pharmacology may contribute to variations in brain response to antidepressants. We examined the impact of two antidepressants with differential actions on serotonin transporter and the 5-HHTLPR-S/Lg polymorphisms on amygdala responses in major depressive disorder (MDD) | ||
| 520 | |a METHODS: Caucasians with MDD were given either citalopram or quetiapine extended release for 8 weeks. Patients were genotyped for 5-HTTLPR. Clinical efficacy was assessed using the Hamilton Depression Rating Scale. fMRI responses to negative emotional faces were acquired at baseline, week 1 and week 8. The outcome measure was change in amygdala responses at week 8 | ||
| 520 | |a RESULTS: Citalopram had no effect on amygdala responses in MDD patients with S/Lg alleles at weeks 1 and 8 compared with baseline, whereas it induced changes in amygdala responses in LL homozygotes. By contrast, quetiapine decreased amygdala responses at both time points in S/Lg carriers, and changes in amygdala responses at week 8 correlated with a reduction in depression scores. The small number of LL homozygotes in quetiapine group was a limitation. Efficacy of both treatments was comparable | ||
| 520 | |a CONCLUSIONS: These preliminary data suggest that pharmacological mechanisms and genetics need to be considered in the development of neuroimaging markers for the evaluation of antidepressant treatments | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a 5-HTTLPR | |
| 650 | 4 | |a amygdala | |
| 650 | 4 | |a antidepressants | |
| 650 | 4 | |a brain imaging | |
| 650 | 4 | |a depression | |
| 650 | 7 | |a Delayed-Action Preparations |2 NLM | |
| 650 | 7 | |a SLC6A4 protein, human |2 NLM | |
| 650 | 7 | |a Serotonin Plasma Membrane Transport Proteins |2 NLM | |
| 650 | 7 | |a Citalopram |2 NLM | |
| 650 | 7 | |a 0DHU5B8D6V |2 NLM | |
| 650 | 7 | |a Quetiapine Fumarate |2 NLM | |
| 650 | 7 | |a 2S3PL1B6UJ |2 NLM | |
| 700 | 1 | |a Burgess, Ashley |e verfasserin |4 aut | |
| 700 | 1 | |a Gaxiola-Valdez, Ismael |e verfasserin |4 aut | |
| 700 | 1 | |a Cortese, Filomeno |e verfasserin |4 aut | |
| 700 | 1 | |a Clark, Darren |e verfasserin |4 aut | |
| 700 | 1 | |a Kemp, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Goodyear, Bradley |e verfasserin |4 aut | |
| 700 | 1 | |a Macqueen, Glenda |e verfasserin |4 aut | |
| 700 | 1 | |a Bech-Hansen, N Torben |e verfasserin |4 aut | |
| 700 | 1 | |a Foster, Jane |e verfasserin |4 aut | |
| 700 | 1 | |a Diwadkar, Vaibhav A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Human psychopharmacology |d 1995 |g 31(2016), 2 vom: 01. März, Seite 144-55 |w (DE-627)NLM086748149 |x 1099-1077 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2016 |g number:2 |g day:01 |g month:03 |g pages:144-55 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/hup.2521 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2016 |e 2 |b 01 |c 03 |h 144-55 | ||